Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$284.00K$284.00K+278.7% vs Q2 2025 Net Income-$127.12M-$127.12MN/M vs Q2 2025 EPS, diluted—
Operating Income-$126,268,000N/M Operating Cash Flowderived-$105,324,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$106,630,000N/M Margins · derivedOperating margin-44460.6%+97895.4 pt vs Q2 2025
Net margin-44760.2%+89553.1 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end